Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways ... For additional information, please visit the Company’s website at ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

For example, it can play a valuable role in supporting any organisation’s sales and marketing efforts via sales clustering ..

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Google.org, the philanthropic arm of the tech giant, has awarded a USD 1 million grant to Mumbai-based non-profit organisation Karya to boost upskilling of low-income communities. The grant will ...

Google.org awards USD 1 million to Karya, an Indian non-profit, to empower low-income communities with AI skills, creating ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...